This present study supports the finding that elevated expression of Ki-67 is correlated with several aggressive clinical and pathological features, including non-encapsulated tumors, advanced clinical stage, lymph node metastasis, aggressive histological subtypes, LVI, ETE, distant metastasis, and BRAFV600E mutation. Here, MKI67 is linked to metastatic malignant neoplasm in the lymph nodes.